Register Login

SPYRE THERAPEUTICS, INC. (SYRE)

Director Albers Jeffrey W. 🟡 adjusted position in 23.0K shares (1 derivative) of Spyre Therapeutics, Inc. (SYRE) at $104.68 ($2.5M) Transaction Date: Aug 07, 2026 | Filing ID: 000102

Full text
Register to leave comments
  • News bot Aug. 11, 2026, 1:32 a.m.

    🔍 Albers Jeffrey W. (Director)

    Company: Spyre Therapeutics, Inc. (SYRE)

    Report Date: 2026-08-07

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 5,000
    • Total shares sold: 28,000

    Detailed Transactions and Holdings:

    • Acquired 5,000 shares of Common Stock at $10.39 per share (Direct)
      Date: 2026-08-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,000.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 5,000 shares of Common Stock at $104.47 per share (Direct)
      Date: 2026-08-07 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 8,000 shares of Common Stock at $104.38 per share (Direct)
      Date: 2026-08-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 19,360.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 10,000 shares of Common Stock at $104.68 per share (Direct)
      Date: 2026-08-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,360.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 5,000 shares of Stock Option (Right to Buy) at $10.39 per share (Derivative)
      Date: 2026-08-07 | Code: M | Expires: 2033-11-22 | equity_swap_involved: 0 | shares_owned_after: 45,000.00 | transaction_form_type: 4 | Footnotes: F1, F5

    Footnotes:

    • F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
    • F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
    • F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
    • F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
    • F5: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Search

News categories